Nick Birrell
Keine laufenden Positionen mehr
Profil
Dr. Nick Birrell joined Innovation Capital as Venture Executive in 2006.
He has over 25 years experience in science, technology and finance.
He has held a wide range of roles ranging from General Manager of a technology start up to CEO of a Australian investment management company.
His most recent executive position was Regional Director, Asia Pacific for global investment management company Invesco.
These roles have involved him in information technology consulting, systems development and project management, providing financial advice to governments and major corporations, managing large dollar investment portfolios and managing employees spread over several continents.
He has previously been an active angel investor in both information technology and biotechnology start-ups and has provided advice and mentoring to CEOs of such companies.
He has a particular interest in the commercialisation of advanced scientific research.
He is a Professorial Fellow in the Faculty of Medicine, Nursing and Health Science at Monash University and is the foundation Director of the Monash Asia Pacific Centre for Science and Wealth Creation.
Ehemalige bekannte Positionen von Nick Birrell
| Unternehmen | Position | Ende |
|---|---|---|
Opto Global Pty Ltd.
 Opto Global Pty Ltd. Medical SpecialtiesHealth Technology Opto Global is a privately owned company focused on sales, marketing and development of ophthalmic equipment. The company is based in Adelaide, South, from where it distributes its products to over 60 countries through local independent distributors. The company's vision is to deliver superior returns to shareholders through a focus on sales and development of ophthalmic products to the global market. Opto Global is committed to development and commercialisation of new technologies for the treatment and diagnosis of diseases of the eye resulting in cutting edge products for ophthalmologists, optometrists, hospitals and associated health care professionals. Opto Global was incorporated in April 2003 and is building on its profitable foundations to deliver new market leading products. Some of the most recent product innovations include the Opto AP200 Automated Perimeter, the world's first solid state blue on yellow automated perimeter for the early diagnosis of glaucoma; the Opto i-MP (Indocyanine green Mediated Photothrombosis) which is progressing through clinical trials with the intention of treating a significant amount of people with Age-related Macular Degeneration (AMD); and, Opto Global is developing an innovative device to assist in cataract surgery which has become the most frequent ophthalmic surgical procedure around the world. | Direktor/Vorstandsmitglied | 19.07.2013 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Opto Global Pty Ltd.
Opto Global Pty Ltd. Medical SpecialtiesHealth Technology Opto Global is a privately owned company focused on sales, marketing and development of ophthalmic equipment. The company is based in Adelaide, South, from where it distributes its products to over 60 countries through local independent distributors. The company's vision is to deliver superior returns to shareholders through a focus on sales and development of ophthalmic products to the global market. Opto Global is committed to development and commercialisation of new technologies for the treatment and diagnosis of diseases of the eye resulting in cutting edge products for ophthalmologists, optometrists, hospitals and associated health care professionals. Opto Global was incorporated in April 2003 and is building on its profitable foundations to deliver new market leading products. Some of the most recent product innovations include the Opto AP200 Automated Perimeter, the world's first solid state blue on yellow automated perimeter for the early diagnosis of glaucoma; the Opto i-MP (Indocyanine green Mediated Photothrombosis) which is progressing through clinical trials with the intention of treating a significant amount of people with Age-related Macular Degeneration (AMD); and, Opto Global is developing an innovative device to assist in cataract surgery which has become the most frequent ophthalmic surgical procedure around the world. | Health Technology |
